Punctal Plug Sustained Drug Release for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, which primarily focus on reducing intraocular pressure, are unable to halt the progressive vision loss associated with the condition, and there is a need for a more effective and sustained delivery method for glaucoma medications.
Innovation Solution
A drug-delivery device comprising a composite of inert particles adsorbed with a drug, a bulking agent, an adhesive binder, and an optional coating, designed to provide sustained release of therapeutic agents, such as Latanoprost and Timolol, directly to the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glaucoma medications are administered using conventional methods, then intraocular pressure can be reduced, but the treatment cannot halt progressive vision loss and requires frequent dosing
Solution Approach 1:
The patent incorporates glaucoma medications into a punctal plug during manufacturing, pre-loading the device with therapeutic agents. This preliminary action allows the medication to be delivered sustainably over time after insertion, eliminating the need for frequent dosing while maintaining effectiveness in reducing intraocular pressure and halting vision loss progression.
Solution Approach 2:
The punctal plug is designed to release medications continuously over an extended period (e.g., 30 days) through controlled diffusion and dissolution mechanisms. This continuous delivery ensures sustained therapeutic levels of the medication in the eye, providing reliable protection against vision loss without requiring repeated administration.
2Reliability
If glaucoma medications are delivered using sustained-release methods, then treatment effectiveness is improved, but the device complexity increases
Solution Approach 1:
The punctal plug utilizes porous materials as the matrix for medication incorporation. These porous structures naturally facilitate controlled drug release through diffusion and dissolution mechanisms, achieving sustained delivery without requiring complex mechanical or chemical release systems. The porosity itself becomes the release mechanism, simplifying the overall device structure.
Solution Approach 2:
The device employs composite materials combining the punctal plug base material with medication-loaded porous particles. This composite approach allows the medication to be embedded within the plug structure, enabling sustained release through the natural properties of the composite materials without adding complex delivery mechanisms.
3Adaptability or versatility
If multiple medications are incorporated into the punctal plug, then comprehensive glaucoma treatment is achieved, but the manufacturing precision requirements increase
Solution Approach 1:
Multiple medications are pre-loaded into the porous particles during manufacturing before incorporation into the punctal plug. This preliminary loading ensures consistent drug distribution and concentrations are achieved during the manufacturing process, reducing precision requirements for the final assembly step while enabling combination therapy.
Solution Approach 2:
The use of porous particles as medication carriers simplifies the incorporation of multiple drugs. The porous structure allows different medications to be loaded separately or simultaneously into the same particle population, and each drug releases independently through diffusion and dissolution, reducing the complexity of managing multiple active agents in the final device.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device enables the sustained release of glaucoma medications, potentially slowing or arresting progressive vision loss by maintaining effective drug levels in the eye over an extended period.
Implementation Method 1
particles of inert materials, where the inert materials are adsorbed with drug on surface of particles (e.g., drug bound to particles) or inside porosity (e.g., drug housed within pores)
Data Source
AI summary
In some embodiments, the present invention is a composition, including: a bulking agent, where the bulking agent is a kaolin, an absorbent material, where the absorbent material is a fumed silica, a binder, where the binder is an epoxy, and a first active agent, where the first active agent is Latanoprost.